

Benzodiazepine Use, Cognitive Impairment, and Cognitive-Behavioral Therapy for Anxiety Disorders: Issues in the Treatment of a Patient in Need

Michael W. Otto, Ph.D.; Steven E. Bruce, Ph.D.;
and Thilo Deckersbach, Ph.D.

Cognitive-behavioral therapy (CBT) is effective in the treatment of anxiety disorders when used in conjunction with benzodiazepine pharmacotherapy and when used as a monotherapy. Patients using CBT alone have dropout rates similar to or lower than those patients undergoing other forms of therapy, including benzodiazepines. CBT also works well with patients who do not respond adequately to pharmacotherapy. Combined CBT and benzodiazepine treatment has additive effects when compared with benzodiazepine monotherapy; however, patients receiving combined therapy who subsequently discontinue benzodiazepine treatment experience a loss of efficacy compared with CBT and placebo, perhaps due to fear extinction being context dependent. To avoid this loss of efficacy, CBT may be administered alone or as a bridge between benzodiazepine use and discontinuation during a medication taper. The case report upon which this supplement is based questions the value of CBT for patients experiencing cognitive impairment due to an anxiety disorder, benzodiazepine medication, substance abuse, or a combination of these factors. This article addresses this concern and asserts that CBT is a valuable treatment option in these cases. *(J Clin Psychiatry 2005;66(suppl 2):34–38)*

The case report¹ that motivated this supplement was noteworthy for raising questions about when cognitive-behavioral therapy (CBT) should be added to benzodiazepine treatment for an anxiety disorder in a patient with cognitive impairment. The case report raises questions about the impact of benzodiazepines on cognitive functioning, the impact of impaired cognitive functioning on CBT outcome, and issues concerning the interactions between CBT and benzodiazepines for both acute and longer term outcome. In this article, we address each of these issues and argue for a crucial role for CBT in the treatment of anxiety disorders, particularly in individuals who are being considered for medication discontinuation. In the following sections, our strategy is to consider current use patterns for benzodiazepine treatment for panic

disorder, and then to consider the evidence for combined CBT and benzodiazepine use. For this discussion, we rely heavily on studies of panic disorder, both because of its potential relevance to the case presented and also because the panic disorder literature is particularly well-developed relative to the issues to be considered. Following general consideration of combined treatment, we then consider the evidence for and implications of cognitive impairment for an individual taking benzodiazepines for phobic anxiety.

BENZODIAZEPINE TREATMENT FOR ANXIETY DISORDERS

Results from the Harvard/Brown Anxiety Research Project (HARP),² a prospective, longitudinal study of anxiety disorders, indicate that benzodiazepines were the most common class of drugs used for panic disorder over the past decade (1989–2001). Sixty-four percent of patients reported receiving a benzodiazepine at intake, and 58% reported receiving a benzodiazepine at the 10-year follow-up. In contrast, rates of selective serotonin reuptake inhibitor (SSRI) usage lagged well behind at the 10-year follow-up (33%).

A previous HARP investigation by Mueller et al.³ examined a total of 343 participants who at intake were taking benzodiazepines, 29% of whom had a past or current history of alcohol use disorder. Examination of daily dose or the supplemental (p.r.n.) use of benzodiazepines over

From the Department of Psychology and Center for Anxiety and Related Disorders, Boston University, Boston, Mass. (Dr. Otto); the Department of Psychiatry and Human Behavior, Brown University, Providence, R.I. (Dr. Bruce); and Massachusetts General Hospital, Harvard Medical School, Boston, Mass. (Dr. Deckersbach).

This article is derived from the roundtable discussion "Utilizing Benzodiazepines in Clinical Practice: An Evidence-Based Discussion," which was held August 16, 2004, in Boston, Mass., and supported by an unrestricted educational grant from Pfizer Inc.

Corresponding author and reprints: Michael W. Otto, Ph.D., Boston University Center for Anxiety and Related Disorders, 648 Beacon St., 6th Floor, Boston, MA 02215.

the first 12 months of follow-up revealed no significant differences between participants with alcohol use disorder and those without alcohol use disorder, suggesting that for these patients there was no evidence for differential dose escalation. In a subsequent examination of 12 years of follow-up data in HARP patients with comorbid alcohol dependence and anxiety disorders, there was no relationship between the use of benzodiazepines and the occurrence of a new alcohol use disorder (T. Mueller, M.D.; M. E. Pagano, Ph.D.; B. F. Rodriguez, Ph.D.; et al., manuscript submitted). Additionally, there was no temporal relationship between the onset of a new alcohol use disorder and the use of benzodiazepines. Moreover, little evidence exists that the intensity (dose, duration) of benzodiazepine use is associated with the onset, recovery, or subsequent recurrence of alcohol use disorder.^{4,5} These data suggest that the relative risk of benzodiazepine use as a predictor of the onset or subsequent course of an alcohol use disorder is minimal. Accordingly, the case¹ presented here appears to represent an atypical or limited-event outcome, rather than the expected outcome for benzodiazepine use for panic disorder.

COMBINED CBT AND BENZODIAZEPINE TREATMENT

Cognitive-behavioral therapy is both an effective alternative to benzodiazepine treatment and a useful adjunctive or replacement treatment for individuals who have failed to respond adequately to benzodiazepine medication. Large-scale studies and meta-analytic reviews⁶⁻¹¹ indicate that CBT is an effective and tolerable treatment for anxiety disorders, with dropout rates that tend to be equal to or below those for medication alternatives, including benzodiazepines. Also, among the few and generally small-scale studies¹²⁻¹⁴ of patients with panic disorder who have been referred to CBT after failing to respond adequately to medications, there is every indication that CBT works well with these patients; however, this evidence is based on benzodiazepines used alone or in combination with SSRIs in a fixed-dose format, and there are some concerns that p.r.n. (as needed) benzodiazepine use may inhibit CBT outcome to a greater extent than regularly scheduled use.¹⁵

Positive open studies indicating benefit for CBT added to benzodiazepine join evidence from a large-scale, randomized trial¹⁶ comparing the acute benefits of combined CBT and benzodiazepine treatment, relative to these treatments offered with placebo or relaxation training, respectively. Additive effects were evident for some measures for acute treatment, but subsequent discontinuation of the benzodiazepine treatment was associated with loss of efficacy of the combined condition relative to CBT plus placebo.

This apparent attenuation of CBT efficacy wrought by discontinued benzodiazepine treatment is worthy of fur-

ther explanation, particularly in relation to evidence on the nature of exposure effects coming from the animal laboratory. Specifically, there is consistent evidence that extinction of conditioned fears (brought by repeated exposure to the feared stimulus in the absence of aversive outcomes) is dependent on the context of extinction.¹⁷ For example, if a fear is conditioned (e.g., pairing of tone and shock so that the animal shows evidence of fear in response to the tone) in one context (Context A), and then is extinguished in a second context (Context B), then the degree of fear that is evoked by later exposure to the once-feared cue (the tone) is dependent on the context in which it appears; if retested in Context A, there is relatively greater return of fear behaviors than in Context B. There is also greater return of fear if an animal conditioned to fear in Context A, then extinguished in Context B, is then tested in a novel context (Context C). These general findings are reliable for a range of contexts including the nature of the testing room (e.g., type and smell of the testing apparatus), as well as recent events and the passage of time (for review see Bouton¹⁷).

There is also evidence that contexts include the internal state of the animal, including drug context. It is these results that are most relevant to the issue of benzodiazepine discontinuation following medication treatment. For example, in animals, Bouton et al.¹⁸ evaluated the effects of changing internal contexts as manipulated by use of benzodiazepine or saline injections. As with the previous studies, there was a greater return of fear when context was shifted between extinction and later testing.

We have applied these findings to interpreting the loss of efficacy when patients who completed CBT on medication later discontinue their medication.^{19,20} This effect is evident not only in the Marks et al.¹⁶ trial of combination treatment with benzodiazepine medication, but also in the large multicenter trial²¹ of the relative and combined efficacy of CBT and imipramine. In both trials, combined treatment had some advantages over either monotherapy alone, but when the medication was discontinued (when the internal context was shifted), learned safety was compromised in the patients who had received the combined treatment, to a level below that for CBT alone. Patients who had not taken then-discontinued medication did not undergo a shift in internal context, and their maintenance of treatment gains was correspondingly stronger. There is also some evidence that attributions about the treatment context may account for some of the disruptive effects of benzodiazepine discontinuation in the Marks et al. trial.¹⁶ Basoglu and associates²² examined the link between attribution and relapse by asking patients who had responded to treatment how much they attributed their gains to medication versus their own efforts. Patients who had attributed their improvement to medication reported significantly more withdrawal symptoms and showed greater loss of gains during the tapering-off and treatment-free

period compared to those who had attributed their gains to their own efforts (see also Biondi and Picardi²³).

These interpretations of multicenter trial data are also consistent with human studies that have manipulated internal context (drug) effects in a controlled fashion.²⁴ In an elegant study, Mystkowski et al.²⁴ investigated shifts in internal context brought by the double-blind ingestion of either caffeine or placebo in a sample of spider-phobic individuals undergoing exposure treatment. After extinction in either the caffeine or placebo condition, maintenance of fear reduction from exposure was assessed 1 week later under congruent (e.g., caffeine extinction and caffeine testing or placebo extinction and placebo testing) or incongruent (caffeine extinction and placebo testing or the reverse) conditions. Patients tested under the incongruent condition had greater return of fear.

Taken together, the body of evidence provided by animal studies,^{17,18} limited study of internal context effects in phobic humans,²⁴ and the pattern of results of multicenter trials^{16,21} are consistent in indicating a risk for relapse brought by combination treatment relative to CBT alone, under conditions of an internal context shift brought by the later discontinuation of pharmacotherapy.

Two immediate solutions to this risk of relapse are evident: (1) patients may continue pharmacotherapy chronically (trying to avoid a context shift) or (2) care can be taken to insure that CBT is used to “bridge the gap” across the internal context shift (that is, CBT would be applied during and after a taper in medication). Certainly, for the treatment of panic disorder, there is evidence for strong maintenance or extension of treatment gains when CBT is applied in a discontinuation program. By fading medication use in the context of CBT, patients are provided with successful experiences with exposure across internal contexts—the result is strong maintenance of treatment gains as evaluated in studies of both benzodiazepine^{25–27} and SSRI^{28,29} treatment. This method of fading medication use in the context of exposure is exactly the way some psychopharmacologists apply benzodiazepine treatment—as a temporary rather than a chronic approach to phobic avoidance. Benzodiazepines are prescribed for initial exposure attempts, but are faded over time, so that the patients achieve successful exposure during and after medication discontinuation. However, given evidence of strong acceptability and tolerability of CBT for large samples of anxiety patients,^{6–11} it is not clear whether many patients truly “need” introduction of benzodiazepines in the first place.

In summary, studies of CBT for anxiety disorders, particularly panic disorder, provide evidence that CBT should be considered an efficacious strategy for an anxiety patient already taking benzodiazepines. CBT can be added with plans for continued benzodiazepine use; conversely, there is evidence that CBT can be used to provide patients with a long-lasting alternative to benzodiazepine use. These con-

siderations are apt for general issues of combined CBT and benzodiazepine treatment, but what of concerns of the effects of memory impairment, potentially associated with benzodiazepine use?

BENZODIAZEPINES AND NEUROPSYCHOLOGICAL DYSFUNCTION

Transient effects following intake of a single dose of a benzodiazepine include increased sedation, impairments in reaction times and psychomotor skills that involve focused attention and visuomotor coordination, and impairment in some functions of working memory.^{30,31} Perhaps one of the most consistently reported effects of a single dose intake of a benzodiazepine on memory is a dose-dependent transient impairment in the acquisition (learning) of new information presented after drug administration (for review see Curran³²). Following intake, benzodiazepine-participants learn fewer words in tests presenting multiple learning trials than placebo participants.³⁰ Likewise, benzodiazepine-administered participants also have difficulties in free recall of information presented after drug administration upon short and long delays, or recognizing this information on recognition tests³¹; however, there is evidence that individuals develop some tolerance to the psychomotor, cognitive, and amnesic effects of benzodiazepines after several weeks of intake.³¹ Studies of individuals with long-term benzodiazepine use for months or years suggest that full tolerance to the amnesic effects of benzodiazepine may not occur. For example, Curran and Birch³³ found impaired memory during and after 2 months of treatment with alprazolam, and residual impairments were still manifest several weeks after drug withdrawal. Consistent with this finding, Bergman et al.³⁴ and Tonne et al.³⁵ reported impairment in verbal or nonverbal learning and memory following chronic benzodiazepine use for several years. In addition, longer intake at higher dosages appears to be associated with more difficulties in verbal learning.³⁶ Studies investigating benzodiazepine effects have failed to exclude patients with serious psychiatric conditions, in particular anxiety disorders for which benzodiazepines are often prescribed. Memory impairment observed after chronic benzodiazepine treatment may reflect effects of anxiety disorders themselves rather than effects of chronic benzodiazepine treatment.

MEMORY IMPAIRMENT IN ANXIETY DISORDERS

Neuropsychological studies of panic disorder have provided mixed evidence for impairments in learning and memory. For example, Lucas et al.³⁷ found impaired verbal and nonverbal learning and memory in patients with panic disorder. Memory impairments remained statistically significant when effects of anxiolytic medications

were statistically controlled. Asmundson et al.³⁸ showed that unmedicated, nondepressed patients with panic disorder exhibited difficulties in learning a 16-item shopping list over 5 learning trials presented in the California Verbal Learning Test, whereas Gladstjo et al.³⁹ failed to find evidence for neuropsychological impairment in patients with panic disorder. Recent findings by our group⁴⁰ suggest that impairments in learning and long-term memory in patients with panic disorder are associated with the disorder itself, rather than long-term benzodiazepine intake. That is, we compared groups of patients with panic disorder who had either taken benzodiazepines for several months or were medication free. Although verbal learning and memory were preserved in both patient groups, patients with panic disorder were impaired in non-verbal learning and memory. However, benzodiazepine-medicated patients did not differ from medication-free patients with panic disorder.

In summary, the available evidence on the nature of memory functioning in benzodiazepines in individuals with anxiety disorders does not provide a firm answer on whether the anxiolytic actions of benzodiazepines provide a balance to the potential amnesic actions of benzodiazepines. What is certain is that patients taking benzodiazepines chronically do effectively learn CBT and achieve treatment benefit. However, these findings do not address whether CBT efficacy is seriously compromised by cognitive impairment. To address this question, it is helpful to consider research on substance use disorders, where this issue has been more consistently investigated.

SUBSTANCE ABUSE, COGNITIVE DYSFUNCTION, AND PSYCHOSOCIAL TREATMENT OUTCOME

Examination of the substance use literature, particularly for alcohol abuse disorders, is especially relevant to the case¹ presented for this series. In the case series, alcohol use in conjunction with benzodiazepine use, and cognitive impairment, were essential features. The alcohol literature provides consistent evidence of neurocognitive impairments from alcohol abuse (for review see Bates et al.⁴¹). However, does this impairment translate to poorer treatment outcome?

Despite clear expectations for compromised treatment effects, research on this topic has been limited and characterized by inconsistent findings.⁴¹ There are some indications of poorer response to treatment for patients with worse cognitive impairment, but other studies^{41,42} do not provide consistent findings. Some of this inconsistency may be due to heterogeneity of treatments being investigated. For example, among structured cognitive-behavioral treatments, as compared to supportive or motivational treatments, select learning or memory deficits may have a clearer role in modulating treatment. In addition, treatment engagement does appear to have a more

reliable link to cognitive impairment as assessed by treatment dropout⁴²⁻⁴⁴ and poorer motivation to change substance-use patterns.^{45,46} Accordingly, given findings of neuropsychological impairment in the patient presented,¹ treatment with CBT may need to attend particularly to motivational factors and the meaning of poor initial treatment adherence, should it occur.⁴⁴

OVERALL SUMMARY AND CONCLUSIONS

In this article, we considered different perspectives on whether CBT is likely to be successful in a patient taking benzodiazepines and suffering from cognitive impairment. By reviewing the more general combination treatment literature, we found evidence for the benefit of CBT when added to chronic benzodiazepine treatment for panic disorder. We also discussed that CBT may be particularly important for patients for whom benzodiazepine discontinuation may be indicated; patients with panic disorder are able to maintain or extend their treatment gains when benzodiazepines are discontinued in the context of CBT. Moreover, given recent research^{47,48} on the extension of treatment strategies from CBT for panic disorder to substance use disorders, this strategy is particularly encouraged. Finally, we provided evidence that findings of cognitive impairment are no reason to refrain from a CBT referral, although there is evidence that treatment adherence may require additional attention.

Drug names: alprazolam (Xanax and others), imipramine (Tofranil and others).

Disclosure of off-label usage: The authors have determined that, to the best of their knowledge, imipramine is not approved by the U.S. Food and Drug Administration for the treatment of panic disorder.

REFERENCES

1. Stewart SA. The effects of benzodiazepines on cognition. *J Clin Psychiatry* 2005;66(suppl 2):9-13
2. Bruce SE, Vasile RG, Goisman RM, et al. Are benzodiazepines still the medication of choice for patients with panic disorder with or without agoraphobia? *Am J Psychiatry* 2003;160:1432-1438
3. Mueller T, Goldenberg IM, Gordon AL, et al. Benzodiazepine use in anxiety disordered patients with and without a history of alcoholism. *J Clin Psychiatry* 1996;57:83-89
4. Posternak MA, Mueller TI. Assessing the risks and benefits of benzodiazepines for anxiety disorders in patients with a history of substance abuse or dependence. *Am J Addict* 2001;10:48-68
5. Ciraulo DA, Sands BF, Shader RI. Critical review of liability for benzodiazepine abuse among alcoholics. *Am J Psychiatry* 1988;145:1501-1506
6. Gould RA, Buckminster S, Pollack MH, et al. Cognitive-behavioral and pharmacological treatment for social phobia: a meta-analysis. *Clin Psychol-Sci Pr* 1997;4:291-306
7. Gould RA, Otto MW, Pollack MH. A meta-analysis of treatment outcome for panic disorder. *Clin Psychol Rev* 1995;15:819-844
8. Kobak KA, Greist JH, Jefferson JW, et al. Behavioral versus pharmacological treatments of obsessive compulsive disorder: a meta-analysis. *Psychopharmacology (Berl)* 1998;136:205-216
9. Öst LG. Long-term effects of behavior therapy for specific phobia. In: Mavissakalian MR, Prien RF, eds. *Long-Term Treatments of Anxiety Disorders*. Washington, DC: American Psychiatric Press; 1996:121-170
10. Otto MW, Tuby KS, Gould RA, et al. An effect-size analysis of the rela-

- tive efficacy and tolerability of serotonin selective reuptake inhibitors for panic disorder. *Am J Psychiatry* 2001;158:1989–1992
11. Otto MW, Penave SJ, Pollack RA, et al. Cognitive-behavioral and pharmacologic perspectives on the treatment of posttraumatic stress disorder. In: Pollack MH, Otto MW, Rosenbaum JF, eds. *Challenges in Clinical Practice: Pharmacologic and Psychosocial Strategies*. New York, NY: Guilford Press; 1996:219–260
 12. Otto MW, Pollack MH, Penava SJ, et al. Group cognitive-behavior therapy for patients failing to respond to pharmacotherapy for panic disorder: a clinical case series. *Behav Res Ther* 1999;37:763–770
 13. Otto MW, Pollack MH, Sabatino SA. Maintenance of remission following cognitive-behavior therapy for panic disorder: possible deleterious effects of concurrent medication treatment. *Behav Ther* 1996;27:473–482
 14. Pollack MH, Otto MW, Kaspi SP, et al. Cognitive-behavior therapy for treatment-refractory panic disorder. *J Clin Psychiatry* 1994;55:200–205
 15. Westra HA, Stewart SH. Cognitive behavioural therapy and pharmacotherapy: complementary or contradictory approaches to the treatment of anxiety? *Clin Psychol Rev* 1998;18:307–340
 16. Marks IM, Swinson RP, Basoglu M, et al. Alprazolam and exposure alone and combined in panic disorder with agoraphobia: a controlled study in London and Toronto. *Br J Psychiatry* 1993;162:776–787
 17. Bouton ME. Context, ambiguity, and unlearning: sources of relapse after behavioral extinction. *Biol Psychiatry* 2002;52:976–986
 18. Bouton ME, Kenney FA, Rosengard C. State dependent fear extinction with two benzodiazepine tranquilizers. *Behav Neurosci* 1990;104:44–55
 19. Otto MW. Learning and “unlearning” fears: preparedness, neural pathways, and patients. *Biol Psychiatry* 2002;52:917–920
 20. Otto MW, Smits JA, Reese HE. Combined psychotherapy and pharmacotherapy for mood and anxiety disorders in adults: review and analysis. *Clin Psychol-Sci Pr*. In press
 21. Barlow DH, Gorman JM, Shear MK, et al. Cognitive-behavioral therapy, imipramine, or their combination for panic disorder: a randomized controlled trial. *JAMA* 2000;283:2529–2536
 22. Basoglu M, Marks IM, Kilic C, et al. Alprazolam and exposure for panic disorder with agoraphobia: attribution of improvement to medication predicts subsequent relapse. *Br J Psychiatry* 1994;164:652–659
 23. Biondi M, Picardi A. Attribution of improvement to medication and increased risk of relapse of panic disorder with agoraphobia [letter]. *Psychother Psychosom* 2003;72:110–111
 24. Mystkowski JL, Mineka S, Vernon LL, et al. Changes in caffeine states enhance return of fear in spider phobia. *J Consult Clin Psychol* 2003;71:243–250
 25. Hegel MT, Ravaris CL, Ahles TA. Combined cognitive-behavioral and time-limited alprazolam treatment of panic disorder. *Behav Ther* 1994;25:183–195
 26. Otto MW, Pollack MH, Sachs GS, et al. Discontinuation of benzodiazepine treatment: efficacy of cognitive-behavioral therapy for patients with panic disorder. *Am J Psychiatry* 1993;150:1485–1490
 27. Spiegel DA, Bruce TJ, Gregg SF, et al. Does cognitive behavior therapy assist slow-taper alprazolam discontinuation in panic disorder? *Am J Psychiatry* 1994;151:876–881
 28. Schmidt NB, Wollaway-Bickel K, Trakowski JH, et al. Antidepressant discontinuation in the context of cognitive behavioral treatment for panic disorder. *Behav Res Ther* 2002;40:67–73
 29. Whittall ML, Otto MW, Hong JJ. Cognitive-behavior therapy for discontinuation of SSRI treatment of panic disorder: a case series. *Behav Res Ther* 2001;39:939–945
 30. Block RI, Berchou R. Alprazolam and lorazepam effects on memory acquisition and retrieval processes. *Pharmacol Biochem Behav* 1984;20:233–241
 31. File SE, Lister RG. Do lorazepam-induced deficits in learning result from impaired rehearsal, reduced motivation, or increased sedation? *Br J Clin Pharmacol* 1982;14:545–550
 32. Curran HV. Tranquillising memories: a review of the effects of benzodiazepines on human memory. *Biol Psychol* 1986;23:179–213
 33. Curran HV, Birch B. Differentiating the sedative, psychomotor and amnesic effects of benzodiazepines: a study with midazolam and the benzodiazepine antagonist, flumazenil. *Psychopharmacology (Berl)* 1991;103:519–523
 34. Bergman H, Borg S, Holm L. Neuropsychological impairment and exclusive abuse of sedatives or hypnotics. *Am J Psychiatry* 1980;137:215–217
 35. Tonne U, Hiltunen AJ, Vikander B, et al. Neuropsychological changes during steady-state drug use, withdrawal, and abstinence in primary benzodiazepine dependent patients. *Acta Psychiatr Scand* 1995;91:299–304
 36. Golombok S, Lader M. The psychopharmacological effects of premedication, diazepam, and placebo in healthy volunteers. *Br J Clin Pharmacol* 1984;18:127–133
 37. Lucas JA, Telch MJ, Bigler ED. Memory functioning in panic disorder: a neuropsychological perspective. *J Anxiety Disord* 1991;5:1–20
 38. Asmundson GJG, Stein MB, Larsen DK, et al. Neurocognitive function in panic disorder and social phobia patients. *Anxiety* 1994–1995;1:201–207
 39. Gladsjo JA, Rapaport MH, McKinney R, et al. A neuropsychological study of panic disorder: negative findings. *J Affect Disord* 1998;49:123–131
 40. Deckersbach T, Otto MW, Pollack MH, et al. Memory functioning in panic disorder [poster]. Presented at the 33rd meeting of the Association for the Advancement of Behavior Therapy; November 11–14, 1999; Toronto, Ontario, Canada
 41. Bates ME, Bowden SC, Barry D. Neurocognitive impairment associated with alcohol use disorders: implications for treatment. *Exp Clin Psychopharmacol* 2002;10:193–212
 42. Teichner G, Horner MD, Roitzsch JC, et al. Substance abuse treatment outcomes for cognitively impaired and intact outpatients. *Addict Behav* 2002;27:751–763
 43. Aharonovich E, Nunes E, Hasin D. Cognitive impairment, retention and abstinence among cocaine abusers in cognitive-behavioral treatment. *Drug Alcohol Depend* 2003;71:207–211
 44. Fals-Stewart W, Lucente S. Effect of neurocognitive status and personality functioning on length of stay in residential substance abuse treatment: an integrative study. *Psychol Addict Behav* 1994;8:179–190
 45. Blume AW, Davis JM, Schmaling KB. Neurocognitive dysfunction in dually-diagnosed patients: a potential roadblock to motivating behavior change. *J Psychoactive Drugs* 1999;31:111–115
 46. Rinn W, Desai N, Rosenblatt H, et al. Addiction denial and cognitive dysfunction: a preliminary investigation. *J Neuropsychiatry Clin Neurosci* 2002;14:52–57
 47. Novak A, Burgess ES, Clark M, et al. Anxiety sensitivity, self-reported motives for alcohol and nicotine use, and level of consumption. *J Anxiety Disord* 2003;17:165–180
 48. Otto MW, Safren SA, Pollack MH. Internal cue exposure and the treatment of substance use disorders: lessons from the treatment of panic disorder. *J Anxiety Disord* 2004;18:69–87